TY  - BOOK
AU  - Mallick,Umair
TI  - Cardiovascular complications of COVID-19: risk, pathogenesis and outcomes
SN  - 3030900649
AV  - RA644 .C373 2022
PY  - 2022///
CY  - Cham, Switzerland
PB  - Springer
KW  - MEDICAL
N1  - 2; The Epidemiology of CoViD19 and Cardiovascular Diseases; Epidemiology --; Discussion; Virology of CoViD19; Viral Characteristics --; Mechanism of Viral Entry in Cells; An Introduction to the Clinical and Diagnostic Features, and CoViD19 Complications; Clinical Symptomatology --; Sepsis and Complications of CoViD19 --; Important Diagnostic Features; The Pathological Features of CoViD19 Cardiovascular Complications; Key Features of Cardiovascular Pathology; Treatment Options in CoViDI9; Antiviral Agents in CoViD19 --; Amino Quinolones in CoViD19 --; Immune-Based Therapies in CoViD19 --; Potential Anti-inflammatory Mechanisms --; Anticoagulants --; CoViD19 Vaccines; An Introduction to the Pathogenetic Mechanisms of CoViD19 Complications; Acute Pulmonary Injury --; Sepsis and Multi-organ Failure --; Renin Angiotensin System --; Endothelin System --; Immune-Inflammation; Overview of Cytokines and CoViD19; Cytokines --; Cytokine Storm in CoViD19 --; Cytokines in Cardiovascular and Metabolic Diseases; The Renin-Angiotensin System in CoViD19; The Renin Angiotensin System --; The Dynamics of ACE2 Expression in CoViD19 --; ACE2 is a Marker of Severity or a Compensatory Mechanism?; Thrombosis in CoViD19; Mechanisms Promoting Thrombosis in CoViD19; Pathogenesis of CoViD19- Miscellaneous Mechanisms; Regulatory Peptide Systems in CoViD19 --; Miscellaneous Mechanisms; Myocardial Injury in CoViD19; Epidemiology of Myocardial Injury --; Definition, Presentation, and Challenges of Myocardial Injury --; Timing and Assessment of Myocardial Injury --; Biomarkers of Myocardial Injury --; Pathogenesis of the Myocardial Injury; Heart Failure in CoViD19; Epidemiology --; Role of Comorbidities in Heart Failure with CoViD19 --; Biomarkers of Heart Failure in CoViD19 --; Pathogenetic Mechanisms of Heart Failure in CoViD19; Hypertension in CoViD19; Epidemiology --; Complexities in Hypertension and CoViD19 --; CoViD19 Susceptibility and Hypertension --; Pathogenesis; Cardiac Arrhythmias in CoViD19; Epidemiology of Arrhythmias in CoViD19 --; Pathogenesis of Arrhythmias in CoViD19; Acute Coronary Syndromes in CoViD19; Epidemiology of Acute Coronary Syndromes in CoViD19 --; Defining Acute Coronary Syndromes, Challenges in Presentation and Assessment --; Pathogenesis of Acute Coronary Syndromes in CoViD19; Diabetes Mellitus and COVID19; Epidemiology --; Pathogenesis --; Treatment Implications; Obesity and COVID19; Pathogenetic Links - Obesity and CoViD19; The Older Age Adults and CoViD19  --; Epidemiology; Gender Disparity in CoViD19; Epidemiology --; Discrepancies in the Epidemiological Data --; Factors Associated with Gender Dichotomy --; Gender Disparity in Immune Response --; Gender Disparity in ACE2 Mechanisms --; Gender Disparity in Cardiovascular Diseases; An Overview of Quality of Research in CoViD19; Quality Issues in CoViD19 Research and Improvement Initiatives; 2; b
N2  - "Cardiovascular Complications of COVID-19: Risk, Pathogenesis and Outcomes provides answers to the increasing numbers of questions related to heart disease in COVID-19, highlighting the association between these pandemics and including risk factors, mechanisms and how these may impact diverse patients populations. It describes how COVID-19 impacts older patients and those with metabolic illnesses such as obesity and diabetes mellitus, while providing an overview of the observed gender dichotomy among patients. It therefore represents an essential resource not only for all cardiovascular physicians but also for any healthcare professionals managing patients with these diseases or those exploring COVID-19."
ER  -